Théa's Acquisition of Branded Ophthalmic Products from Akorn – Global Legal Chronicle
Willkie Farr & Gallagher advised Akorn, and Weil, Gotshal & Manges advised Théa in the transaction.
Akorn Operating Company LLC, a specialty pharmaceutical company, entered into a definitive agreement to sell seven branded ophthalmic products to Théa, the leading independent European pharmaceutical group in ophthalmology.
The seven established brands included in the transaction are Zioptan®, AcellFX™, Betimol® , Cosopt®, Cosopt® PF, AzaSite® and Akten®.
Théa is an independent pharmaceutical company based in France specializing in the research, development and commercialization of eye-care products.
Akorn develops, manufactures and markets specialty pharmaceuticals, including prescription, consumer health and animal health products.
Perella Weinberg Partners acted as financial advisers to Théa.
The Willkie team was led by partners Russell Leaf (Picture), Thomas Mark and Tiffany Lee and counsel Jeffrey Daniel.
Involved fees earner: Jeffrey Daniel – Willkie Farr & Gallagher; Russell Leaf – Willkie Farr & Gallagher; Tiffany Lee – Willkie Farr & Gallagher; Thomas Mark – Willkie Farr & Gallagher;
Law Firms: Willkie Farr & Gallagher;
Clients: Akorn Inc.;
Contenuto alternativo per i browser che non leggono gli iframe.
User Agreement | Privacy Policy | Technologies Used
Copyright © 2020 · PBV Monitor Srl. All rights reserved. PBV Monitor is a Registered publications at Milan Court Press Register n. 347/2012
PBV Monitor Srl, P.IVA. 03685040127
PBV Monitor Srl
